|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Arrhythmia | |||||
| Cardiovascular Diseases | |||||
| Death, Sudden, Cardiac | |||||
| Heart Diseases | |||||
| Heart Failure, Congestive | |||||
| Heart Failure | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Arrhythmias, Cardiac | |||||
| Death, Sudden | |||||
| 3 | More general conditions related to this trial | ||||
| Death | |||||
| Heart Arrest | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| amiodarone | |||||
| defibrillators, implantable | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Arrhythmia Agents | |||||
| Cardiovascular Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| Vasodilator Agents | |||||
| 6 | Sponsors listed in this trial | ||||
| National Heart, Lung, and Blood Institute (NHLBI) | |||||